Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
In September, 2014, PAION and Yichang Humanwell Pharmaceutical Co. announced an agreement concerning the development and marketing of M6G in China. This drug candidate is a metabolite of morphine. M6G is currently in clinical development by Yichang Humanwell for the treatment of post-operative pain.
The agreement gives Yichang Humanwell the exclusive license to develop, produce and market M6G in China. PAION receives payments totaling EUR 1.6 million. Additional license fees were not agreed.
Additional information is available here:
PAION AG grants license to Yichang Humanwell for M6G in China (September 2014)